Affymax Announces Third Quarter 2012 Financial Results Teleconference and Webcast
Affymax, Inc. (Nasdaq: AFFY) today announced that it will host a
teleconference and webcast with management to provide a general business
overview, as well as to discuss its third quarter 2012 financial results
on Thursday, November 8, 2012 at 4:30 p.m. Eastern Time (1:30 p.m.
Pacific Time). Financial results for the quarter ended September 30,
2012 will be released after market close on November 8, 2012.
Interested parties can listen to the live teleconference by dialing
(866) 393-1565 from the U.S. or +1 (973) 409-9608 for international
callers. Individuals may access the live audio webcast at http://www.investors.affymax.com/events.cfm.
A replay of the webcast will be available on the Company’s website for
30 days following the live event.
About Affymax, Inc.
Affymax, Inc. is a biopharmaceutical company based in Palo Alto,
California. Affymax's mission is to discover, develop and deliver
innovative therapies that improve the lives of patients with kidney
disease and other serious and often life-threatening illnesses.
The company's first marketed product, OMONTYS® (peginesatide)
Injection, was approved by the U.S. Food and Drug Administration (FDA)
in March 2012. For additional information, please visit www.affymax.com.
Affymax, Inc. Alexandra Santos, 650-812-8961 Associate
Director, Corporate Communications